glp-1 news september 30 2025 Agonists: Using Semaglutide, Tirzepatide, and Orforglipron for Weight Loss and Obesity FDA bans compounded GLP-1 drugs

In the UK, NICE recommends GLP-1 receptor agonists for type 2 diabetes in specific circumstances (NG28), such as when metformin is insufficient and BMI 30 kg/m

Additionally, this combination produces long-term effects

With appetites suppressed and portion sizes reduced, every bite needs to contribute towards maintaining muscle mass, contributing fiber, delivering essential nutrients and supporting overall wellness

Most side effects are transient and manageable with appropriate intervention

Providers recommend GLP-1 receptor agonists for patients who cannot tolerate metformin, exceed a hemoglobin A1c (HbA1c) target by more than 1.5%, or fail to achieve glycemic goals within three months of treatment (20)